MedTrace Logo

Cumulative Skin Irritation Potential of a New 25 mg Nicotine Patch

NCT00967174 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-07-10

No results posted yet for this study

Summary

An investigation on the cumulative skin irritation potential of a newly developed 25 mg nicotine patch. Evaluation of skin irritation of a newly developed 25 mg nicotine transdermal patch

Conditions

  • Smoking Cessation

Interventions

DRUG

Nicotine Patch

25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.

DRUG

Placebo Patch

Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.

DRUG

SLS Comparator Patch

0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.

Sponsors & Collaborators

  • McNeil AB

    lead INDUSTRY

Principal Investigators

  • Elisabeth Kruse, PhD · Mc Neil AB

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967174 on ClinicalTrials.gov